MAPKAPK2 and Alzheimer disease: Previous works have revealed that selective MK2 inhibition modulates Aβ or LPS toxicities, but recent studies have demonstrated that MK2 can also control the kinase RIPK1, which is possibly involved in AD pathogenesis [25,26,69].